Please assess the completion status of the following clinical trial:

Trial Title: Antibody and Safety Study of 6 Doses of NicVAX in Smokers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy smoker, ≥10 cigarettes per day for 6 months, exhaled carbon monoxide ≥10 ppm~* Written informed consent~* Negative urine pregnancy test, and willing to use birth control during the study, if applicable~Exclusion Criteria:~* Prior exposure to nicotine vaccine~* Clinically significant allergic reactions, especially to components of the vaccine~* Serious or unstable clinical disease within the past 6 months~* Use of any smoking cessation therapy within 30 days preceding 1st dose~* Immunosuppression, due to: steroids or other immunosuppressants in the last 30 days, history of cancer or cancer treatment in the last 60 months, known HIV infection, or congenital or acquired immunodeficiency~* Use of any vaccine other than influenza vaccine within 30 days prior to each study dose~* Use of another IND drug or device within 30 days preceding 1st dose~* Inability to follow the protocol, or illicit drug use in the past 12 months, or psychiatric disorder in the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NicVAX (Type: EXPERIMENTAL): None
- NicVAX Lot 2 (Type: EXPERIMENTAL): 2nd cohort receives a different lot of vaccine from the 1st cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).